Losartan Reduces Fibrosis and Improves Muscle Strength in Muscular Dystrophy Model
Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse Ann Neurol. 2012 May;71(5):699-708 Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y Abstract OBJECTIVE: Lamininα2-deficient congenital muscular dystrophy type 1A (MDC1A) is a cureless disease associated with severe disability and shortened lifespan. Previous …
Losartan Reduces Fibrosis and Improves Muscle Strength in Muscular Dystrophy Model Read More »